Pliant Therapeutics (PLRX) News Today $1.45 +0.04 (+2.84%) Closing price 04:00 PM EasternExtended Trading$1.45 0.00 (0.00%) As of 05:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock PLRX Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 Time Period Peapod Lane Capital LLC Acquires New Holdings in Pliant Therapeutics, Inc. (NASDAQ:PLRX)July 10, 2025 | marketbeat.comPliant Therapeutics Provides Update on BEACON-IPFJune 27, 2025 | globenewswire.comPliant Therapeutics, Inc. (NASDAQ:PLRX) Receives Average Rating of "Hold" from AnalystsJune 16, 2025 | marketbeat.comResearch Analysts Offer Predictions for PLRX FY2026 EarningsJune 10, 2025 | marketbeat.comAlnylam, Pliant among stocks yet to face Q2 catalysts: Wells FargoJune 7, 2025 | msn.comBank of America Corp DE Has $1.59 Million Position in Pliant Therapeutics, Inc. (NASDAQ:PLRX)June 5, 2025 | marketbeat.comPliant Therapeutics, Inc. (NASDAQ:PLRX) Given Consensus Rating of "Hold" by AnalystsMay 24, 2025 | marketbeat.comPliant Therapeutics presents new fibrosis treatment dataMay 23, 2025 | investing.comFrazier Life Sciences Management L.P. Makes New Investment in Pliant Therapeutics, Inc. (NASDAQ:PLRX)May 23, 2025 | marketbeat.comPliant Therapeutics Presents Clinical and Preclinical Data at the American Thoracic Society International ConferenceMay 21, 2025 | finance.yahoo.comPliant Therapeutics Presents Clinical and Preclinical Data at the American Thoracic Society International ConferenceMay 21, 2025 | globenewswire.comDeutsche Bank AG Buys 1,017,500 Shares of Pliant Therapeutics, Inc. (NASDAQ:PLRX)May 16, 2025 | marketbeat.comGranahan Investment Management LLC Has $6.94 Million Stock Holdings in Pliant Therapeutics, Inc. (NASDAQ:PLRX)May 12, 2025 | marketbeat.comPliant Therapeutics Provides Corporate Update and Reports First Quarter 2025 Financial ResultsMay 8, 2025 | globenewswire.comBarclays PLC Lowers Stock Holdings in Pliant Therapeutics, Inc. (NASDAQ:PLRX)May 6, 2025 | marketbeat.comPliant Therapeutics announces workforce reductionMay 3, 2025 | uk.investing.comPliant Therapeutics Announces Workforce Reduction and Cost Saving Initiatives to Support Late-Stage Clinical TrialsMay 3, 2025 | nasdaq.comBay Area biotech company Pliant Therapeutics slashes staff after losing $655 million in valueMay 2, 2025 | msn.comPliant Therapeutics Announces Strategic Realignment of Workforce and OperationsMay 1, 2025 | globenewswire.com649,660 Shares in Pliant Therapeutics, Inc. (NASDAQ:PLRX) Purchased by Adage Capital Partners GP L.L.C.May 1, 2025 | marketbeat.comPrice T Rowe Associates Inc. MD Sells 200,327 Shares of Pliant Therapeutics, Inc. (NASDAQ:PLRX)May 1, 2025 | marketbeat.comFirst Light Asset Management LLC Has $22.14 Million Stock Position in Pliant Therapeutics, Inc. (NASDAQ:PLRX)April 30, 2025 | marketbeat.comPliant Therapeutics (PLRX) to Release Quarterly Earnings on MondayApril 30, 2025 | marketbeat.comPliant Therapeutics, Inc. (NASDAQ:PLRX) Given Consensus Rating of "Hold" by BrokeragesApril 28, 2025 | marketbeat.comBlue Owl Capital Holdings LP Has $36.47 Million Position in Pliant Therapeutics, Inc. (NASDAQ:PLRX)April 26, 2025 | marketbeat.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Pliant Therapeutics, Inc. – PLRXApril 25, 2025 | globenewswire.comSilverarc Capital Management LLC Makes New $17.33 Million Investment in Pliant Therapeutics, Inc. (NASDAQ:PLRX)April 24, 2025 | marketbeat.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Pliant Therapeutics, Inc. - PLRXApril 21, 2025 | globenewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Pliant Therapeutics, Inc. - PLRXApril 21, 2025 | globenewswire.comVanguard Group Inc. Has $42.52 Million Stake in Pliant Therapeutics, Inc. (NASDAQ:PLRX)April 14, 2025 | marketbeat.comPliant Therapeutics Announces Upcoming Presentations at the 2025 American Thoracic Society International ConferenceApril 7, 2025 | globenewswire.comPliant Therapeutics, Inc. (NASDAQ:PLRX) Sees Significant Growth in Short InterestApril 4, 2025 | marketbeat.comPliant Therapeutics: An Activist On DeckApril 3, 2025 | seekingalpha.comINVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Pliant TherapeuticsMarch 28, 2025 | prnewswire.comINVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Pliant Therapeutics – PLRXMarch 26, 2025 | globenewswire.comINVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Pliant TherapeuticsMarch 23, 2025 | globenewswire.comINVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Pliant Therapeutics - PLRXMarch 21, 2025 | markets.businessinsider.comPliant Therapeutics (NASDAQ:PLRX) Receives Neutral Rating from HC WainwrightMarch 19, 2025 | marketbeat.comINVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Pliant TherapeuticsMarch 19, 2025 | globenewswire.comINVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Pliant TherapeuticsMarch 17, 2025 | markets.businessinsider.comPliant Therapeutics' Investigational Cancer Drug Shows Antitumor Activity Across Multiple Tumor TypesMarch 17, 2025 | benzinga.comPliant Therapeutics announces interim Phase 1 data from PLN-101095March 17, 2025 | markets.businessinsider.comPliant Therapeutics Announces Interim Phase 1 Data for PLN-101095 in Patients with Immune Checkpoint Inhibitor-Refractory Advanced Solid TumorsMarch 17, 2025 | globenewswire.comINVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Pliant TherapeuticsMarch 15, 2025 | globenewswire.comPliant Therapeutics, Inc.: Pliant Therapeutics Adopts Limited Duration Stockholder Rights AgreementMarch 13, 2025 | finanznachrichten.deSHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Pliant TherapeuticsMarch 13, 2025 | prnewswire.comPliant Therapeutics Adopts Limited Duration Stockholder Rights AgreementMarch 13, 2025 | globenewswire.comINVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Pliant TherapeuticsMarch 9, 2025 | globenewswire.comHC Wainwright Issues Optimistic Estimate for PLRX EarningsMarch 8, 2025 | marketbeat.comPliant Therapeutics, Inc. (NASDAQ:PLRX) Receives Consensus Rating of "Hold" from AnalystsMarch 8, 2025 | marketbeat.com Get Pliant Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for PLRX and its competitors with MarketBeat's FREE daily newsletter. Email Address PLRX Media Mentions By Week PLRX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. PLRX News Sentiment▼1.811.01▲Average Medical News Sentiment PLRX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. PLRX Articles This Week▼24▲PLRX Articles Average Week Get Pliant Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for PLRX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies CMPS News AARD News ABEO News GLUE News LFCR News RNAC News IVA News NGNE News FHTX News ZYBT News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:PLRX) was last updated on 7/14/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, an...Brownstone Research | SponsoredBanks aren’t ready for this altcoin—are you?I've never been more confident about a DeFi opportunity. This isn't about complex trading or risky bets. Th...Crypto 101 Media | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | SponsoredCrypto Is Pumping Again – Now Comes the Real OpportunityThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Pliant Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Pliant Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.